The Challenge
In a previous submission in Norway our client was met with several objections to the submitted application and health economic model for their oncology product. The global model was poorly developed, overly complex, and the vendor supporting with the HTA submission in Norway did not fully capture the value proposition. NHTA were brought in to ensure that the previous decision from Decision Forum was overturned, as we had succeeded with this for several other drugs before.
Solution
Our experienced team conducted an initial feasibility analysis that considered whether a resubmission, informed by longer follow-up data and a new bespoke Global health economic model, could result in a different decision outcome.
NHTA developed the conceptual design of the Global cost-effectiveness model based on dialogue with NoMA. Instead of a decision tree + Markov model with 20+ disease states, we developed a more appropriate and user-friendly de-novo CE-model, following a standard three state Partitioned Survival model structure. This model illustrated the clinical benefits of the innovative oncology product much more accurately, was much easier to use and follow and improved the ICER significantly. In parallel with this work, we developed the required statistical analyses (survival analyses) in line with NICE guidance. Finally, our HTA team developed a bespoke submission dossier highlighting the benefits of the technology as well as the potential savings within the healthcare system. Additionally, following the submission we supported the client in the price negotiations.
Impact
We managed, in close collaboration with the client, to build a convincing case that resulted in Decision Forum overturning their original decision, allowing access for the technology in Norway.
